It is very uncertain whether transjugular intrahepatic portosystemic shunts changes all‐cause mortality compared with conventional treatment (very low certainty).
Transjugular intrahepatic portosystemic shunts showed no clear difference in morbidity due to any cause compared with conventional treatment (low certainty).
It is very uncertain whether transjugular intrahepatic portosystemic shunts changes serious adverse events compared with conventional treatment (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether transjugular intrahepatic portosystemic shunts changes participants who did not receive a liver transplant compared with conventional treatment (very low certainty).
Transjugular intrahepatic portosystemic shunts showed no clear difference in participants without improvement in kidney function compared with conventional treatment (low certainty).
It is very uncertain whether surgical portosystemic shunts changes all‐cause mortality at 30 days compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
It is very uncertain whether surgical portosystemic shunts changes all‐cause mortality at 5 years compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
It is very uncertain whether surgical portosystemic shunts changes number of participants with Variceal rebleeding episodes at 30 days compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
It is very uncertain whether surgical portosystemic shunts changes number of participants with reintervention at 5 years compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
It is very uncertain whether surgical portosystemic shunts changes irreversible shunt occlusion at 5 years compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
It is very uncertain whether surgical portosystemic shunts changes number of participants with encephalopathy at 5 years compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes all‐cause mortality compared with endoscopic intervention with or without medical treatment (very low certainty).
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes rebleeding compared with endoscopic intervention with or without medical treatment (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes mortality due to rebleeding compared with endoscopic intervention with or without medical treatment (very low certainty).
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes acute hepatic encephalopathy compared with endoscopic intervention with or without medical treatment (very low certainty).
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes chronic hepatic encephalopathy compared with endoscopic intervention with or without medical treatment (very low certainty).